Regeneron Pharmaceuticals' Assets Average rose 6.61% to $39.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $39.2 billion, marking a year-over-year increase of 6.61%. This contributed to the annual value of $35.4 billion for FY2024, which is 13.72% up from last year.
As of Q3 2025, Regeneron Pharmaceuticals' Assets Average stood at $39.2 billion, which was up 3.46% from $37.9 billion recorded in Q2 2025.
Over the past 5 years, Regeneron Pharmaceuticals' Assets Average peaked at $39.2 billion during Q3 2025, and registered a low of $17.5 billion during Q1 2021.
Over the past 3 years, Regeneron Pharmaceuticals' median Assets Average value was $35.2 billion (recorded in 2024), while the average stood at $34.7 billion.
Data for Regeneron Pharmaceuticals' Assets Average shows a peak YoY skyrocketed of 48.23% (in 2022) over the last 5 years.
Quarterly analysis of 5 years shows Regeneron Pharmaceuticals' Assets Average stood at $24.6 billion in 2021, then rose by 15.86% to $28.4 billion in 2022, then climbed by 14.68% to $32.6 billion in 2023, then climbed by 15.26% to $37.6 billion in 2024, then climbed by 6.61% to $39.2 billion in 2025.
Its Assets Average was $39.2 billion in Q3 2025, compared to $37.9 billion in Q2 2025 and $37.7 billion in Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value